Med-X is gearing up for a possible NASDAQ listing (ticker: MXRX)

Med-X is gearing up for a possible NASDAQ listing (ticker: MXRX). But the real opportunity is now – before public health adoption accelerates. In certain use cases, Med-X's all-natural pesticides have outperformed chemical brands in independent lab tests, delivering safer solutions without sacrificing results. Now, Med-X is approaching a major real-world validation catalyst: Florida Mosquito Control Districts are independently testing Nature-Cide as an adulticide, larvicide, and barrier treatment – with the goal of adding it to their official rotation. Florida has the most well-funded mosquito control districts in the United States and carries the highest responsibility for controlling mosquito-borne threats. These districts are known as leaders and innovators in Integrated Mosquito Management – meaning that when Florida adopts a solution, other regions often follow. And right now, these districts need better options. Public scrutiny over the chemical pesticides traditionally used in mosquito control is rising fast – especially around communities, schools, and waterways. Nature-Cide's plant-based approach offers a potential alternative that aligns with performance demands while reducing toxicity concerns. NASDAQ Ticker: MXRX Reserved The Real Opportunity to Become a Shareholder Is Now! Med-X has earned national and international recognition for providing effective alternatives to conventional pesticides across residential, commercial, and agricultural sectors. Proudly produced in the USA under strict quality standards, Nature-Cide reflects their commitment to sustainable pest management innovation. With $6.4M in sales in just four years, expanding into 41 international markets, Med-X is getting ready for the next step... Simpler. Safer. More Effective Pesticides. Become a Med-X shareholder at $4 per share before their NASDAQ plans unfold. Disclosures This is a paid advertisement for Med-X's Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com

 

 

Notice: Please understand that by opting out from future emails from this advertiser, you are transferring or authorizing the transfer of your email address to the advertiser listed above. Zacks has no control over how your email address is used by the advertiser or other third parties. Accordingly, Zacks disclaims all responsibility and liability arising from the subsequent use of your email address that is made possible by your submission of your email address above. You are receiving this email from Zacks Investment Research because you chose to receive messages from Zacks’ partners on the Zacks web site(s). Please note that Zacks does not produce or endorse this product, and assumes no responsibility for the use thereof. Your privacy is important to us. Click here to see our Privacy Policy: https://www.zacks.com/privacy.php If you do not wish to receive further email solicitations from Zacks on behalf of its partners, please click here to unsubscribe. Zacks Investment Research 101 N Wacker Drive, Suite 1500 Chicago, IL 60606